Novo Nordisk reported better-than-expected third-quarter sales for its weight-loss drug Wegovy, calming investor concerns ...

Key Takeaways Novo Nordisk's U.S.-listed shares rose Wednesday morning as third-quarter profits beat estimates and sales of Ozempic and Wegovy continued to grow.Sales rose 21% from the same time last ...

Novo Nordisk is the company that makes the Ozempic and Wegovy drugs, part of the wildly popular GLP-1 class of drugs that have proven effective in reducing weight and treating diabetes. Demand has ...